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Abstract
The linear ubiquitin chain assembly complex (LUBAC) is the only
known E3 ubiquitin ligase which catalyses the generation of linear
ubiquitin linkages de novo. LUBAC is a crucial component of various
immune receptor signalling pathways. Here, we show that LUBAC
forms part of the TRAIL-R-associated complex I as well as of the
cytoplasmic TRAIL-induced complex II. In both of these complexes,
HOIP limits caspase-8 activity and, consequently, apoptosis whilst
being itself cleaved in a caspase-8-dependent manner. Yet, by
limiting the formation of a RIPK1/RIPK3/MLKL-containing complex,
LUBAC also restricts TRAIL-induced necroptosis. We identify RIPK1
and caspase-8 as linearly ubiquitinated targets of LUBAC following
TRAIL stimulation. Contrary to its role in preventing TRAIL-induced
RIPK1-independent apoptosis, HOIP presence, but not its activity,
is required for preventing necroptosis. By promoting recruitment
of the IKK complex to complex I, LUBAC also promotes TRAIL-
induced activation of NF-jB and, consequently, the production of
cytokines, downstream of FADD, caspase-8 and cIAP1/2. Hence,
LUBAC controls the TRAIL signalling outcome from complex I
and II, two platforms which both trigger cell death and gene
activation.
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Introduction
The tumour necrosis factor (TNF)-related apoptosis-inducing ligand
(TRAIL) is a member of the TNF superfamily of cytokines identified
based on its homology to CD95 ligand (CD95L) and TNF (Wiley
et al, 1995; Pitti et al, 1996). Systemic treatment of tumour-bearing
mice with recombinant TRAIL can efficiently kill tumour cells with-
out inducing any toxicity and was suggested to be a promising new
avenue for cancer treatment (Ashkenazi et al, 1999; Walczak et al,
1999). However, the therapeutic benefit of TRAIL receptor (TRAIL-R)
agonists in clinical studies has been limited as cancer cells develop
resistance and, in some instances, TRAIL promotes tumorigenesis
(Micheau et al, 2013; von Karstedt et al, 2015). This points out
the need for designing novel TRAIL-R agonists (Tuthill et al,
2015; de Miguel et al, 2016) and improving the understanding of
TRAIL-induced apoptotic and non-apoptotic signalling (Lemke et al,
2014; Ashkenazi, 2015). Binding of TRAIL to TRAIL-R1 (also known
as death receptor 4, DR4) and TRAIL-R2 (also known as DR5 or
KILLER) induces formation of the death-inducing signalling complex
(DISC), also termed complex I, composed of FADD, caspase-8/10
and cFLIPL/S (Kischkel et al, 1995, 2000, 2001; Sprick et al, 2000,
2002). Formation of the DISC/complex I leads to the activation of
initiator caspases 8 and 10 which results in cleavage and activation
of effector caspases 3 and 7. This in turn triggers downstream
effector mechanisms of apoptosis. TRAIL-induced apoptotic signal-
ling is tightly regulated at multiple stages. For instance, cFLIPS
abrogates initiator caspase-8 activation, whereas cFLIPL enables
DISC-restricted activation of caspase-8 (Hughes et al, 2016). More-
over, Bcl-2 family members as well as the caspase-3 and caspase-9
inhibitor XIAP modulate TRAIL-induced death (Lemke et al, 2014).
Besides promoting apoptosis, TRAIL has also been shown to be
capable of triggering necroptosis, a caspase-independent type of cell
death requiring RIPK1, RIPK3 and MLKL (Holler et al, 2000; Jouan-
Lanhouet et al, 2012; Goodall et al, 2016). TRAIL also triggers death
domain (DD)-dependent gene-activatory signalling which initiates
non-cytotoxic outcomes, including cytokine production (Azijli et al,
2013). The initiation of gene-activatory signalling is thought to
emanate from complex II, a secondary cytoplasmic signalling
complex. This complex comprises RIPK1, NEMO, TRAF2, caspase-8
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and FADD but is devoid of TRAIL-R1/R2 (Varfolomeev et al, 2005).
Furthermore, whilst cFLIPL has been proposed to modulate gene-
activatory signalling, it remains unresolved whether it acts as a posi-
tive or negative regulator of gene activation (Kataoka et al, 2000;
Kataoka & Tschopp, 2004; Golks et al, 2006; Kavuri et al, 2011). In
addition, we recently showed that TRAIL/TRAIL-R exerts death
domain (DD)-independent, pro-tumorigenic and pro-metastatic
functions in KRAS-mutated cancer cells (von Karstedt et al, 2015).
In summary, TRAIL can induce several distinct signalling outcomes
ranging from cell death, via apoptosis or necroptosis, to gene activa-
tion, cytokine production and migration. The molecular mecha-
nisms, especially with regard to posttranslational modification(s),
which provide the basis for these different outcomes, are so far not
well defined.
Ubiquitination is the attachment of the C-terminal glycine of a
ubiquitin to an amino group on a target protein, usually on a
lysine (K) residue (Hershko & Ciechanover, 1998). Ubiquitin itself
can be the target for ubiquitination, leading to the formation of
different di-ubiquitin linkages. This can be repeated to result in
the formation of ubiquitin chains which can directly affect the
function of target proteins but also recruit specific ubiquitin bind-
ing molecules (Husnjak & Dikic, 2012; Komander & Rape, 2012).
Apart from the e-amino groups of the seven lysines on the target-
attached ubiquitin, also the a-amino group of the N-terminal
methionine of ubiquitin can be used to create an inter-ubiquitin
linkage. In the latter case, the result is the formation of the
so-called linear or methionine 1 (M1) linkage. The linear ubiqui-
tin chain assembly complex (LUBAC), composed of SHARPIN,
HOIL-1 and the catalytic component HOIP, is the only ubiquitin
E3 currently known to form such chains de novo (Kirisako et al,
2006; Tokunaga et al, 2009). LUBAC and linear ubiquitination are
now considered to be important regulators of multiple signalling
pathways (Walczak et al, 2012; Fiil & Gyrd-Hansen, 2014; Ikeda,
2015; Sasaki & Iwai, 2015; Shimizu et al, 2015). In TNF signal-
ling, LUBAC stabilises the TNF receptor 1 signalling complex
(TNFR1-SC) and prevents formation of the cytoplasmic death-
inducing complex (Haas et al, 2009; Peltzer et al, 2014). Aberrant
TNFR1-induced cell death accounts for SHARPIN deficiency-
induced multi-organ inflammation (Gerlach et al, 2011; Ikeda
et al, 2011; Tokunaga et al, 2012; Kumari et al, 2014; Rickard
et al, 2014) and HOIP deficiency-induced embryonic lethality at
mid-gestation (Peltzer et al, 2014).
Interestingly, ubiquitination was recently identified as an addi-
tional level of regulation of TRAIL signalling as cullin-3-mediated
K63-linked ubiquitination of caspase-8 was shown to promote its
activation at the TRAIL DISC whilst TRAF2-dependent K48-linked
ubiquitination was found to trigger its proteasomal degradation
(Jin et al, 2009; Gonzalvez et al, 2012). In addition, pharmacologic
depletion of the ubiquitin E3s cIAP1/2 by SMAC mimetics sensi-
tises cells to TRAIL-induced death (Fulda et al, 2002; Geserick
et al, 2009). However, whether and how LUBAC and M1-linked
ubiquitination modulate TRAIL-induced signalling is currently
elusive.
In this study, we identify LUBAC as a previously unrecognised
component of both, the TRAIL-R-associated signalling complex I
and a secondary, cytoplasmic TRAIL-induced complex II. We
demonstrate that LUBAC is crucial in regulating the balance
between different outcomes of TRAIL-induced signalling, restricting
cell death whilst promoting gene activation. Importantly, our
study shows that complex I of TRAIL signalling does not act
solely as a DISC but is also capable of initiating gene activation,
thereby extending and revising the current model according to
which TRAIL-induced gene-activatory signalling is limited to
complex II.
Results
HOIP limits TRAIL-induced apoptosis and necroptosis
Since K63- and K48-linked ubiquitination regulates TRAIL-induced
cell-death signalling and linear ubiquitination controls multiple
immune signalling pathways, we examined whether LUBAC may be
implicated in TRAIL signalling. Mouse embryonic fibroblasts
(MEFs), which are poorly sensitive to TRAIL-induced cell death,
were significantly sensitised in the absence of HOIP (Fig 1A and
Appendix Fig S1A). We used TNF-deficient MEFs, thereby ruling out
any implication of this cytokine in the observed death. Given that
TRAIL can induce both apoptosis and necroptosis, we investigated
the modality of TRAIL-induced death in HOIP-deficient (HOIP KO)
MEFs. TRAIL-induced cell death of HOIP KO MEFs was not blocked
by the caspase inhibitor z-VAD-fmk (zVAD) but by the combination
of zVAD with the RIPK1 kinase inhibitor Nec-1s (Fig 1B).
TRAIL-induced cleavage of caspases 8, 3 and PARP-1 and
phosphorylation of MLKL were increased in HOIP KO MEFs
(Fig 1C). Therefore, HOIP limits both TRAIL-induced apoptosis and
necroptosis in MEFs.
We next aimed to evaluate the role of HOIP in TRAIL-induced
cell death in human cancer cells. HOIP KO HeLa cells were signifi-
cantly sensitised to TRAIL-induced death (Appendix Fig S1B and C).
This was completely prevented by zVAD, indicating that these cells
undergo apoptosis (Appendix Fig S1D). Similarly, HOIP deficiency
sensitised K562 cells to TRAIL-induced apoptosis (Fig 1D and E, and
Appendix Fig S1E). In accordance, TRAIL-induced cleavage of
caspases 8, 10, 9 and 3 as well as of PARP-1 and Bid was enhanced
in HOIP KO K562 cells (Fig 1F). In line with a previous report (Koo
et al, 2015), RIPK3 is not expressed in K562 and HeLa cells
(Appendix Fig S1F), rendering them unable to undergo necroptosis.
Therefore, HOIP restricts TRAIL-induced cell death, which can be
apoptotic or necroptotic depending on the cell’s ability to die by
these different modalities.
LUBAC is recruited to the TRAIL-R-associated complex I in a
FADD-dependent manner
We and others previously identified the TRAIL-R1/2-associated
complex I as a cell-death initiating platform (Kischkel et al, 2000;
Sprick et al, 2000). As HOIP prevents TRAIL-induced cell death, we
hypothesised that LUBAC might form part of this TRAIL-R-
associated DISC. Indeed, we found that all LUBAC components are
recruited to TRAIL complex I in HeLa and A549 cells (Fig 2A and
B). Reciprocally, caspase-8, TRAIL-R2 and FADD were co-
immunoprecipitated with HOIP in HeLa and K562 cells upon TRAIL
stimulation (Fig EV1A and B). In addition, linear ubiquitin chains
were detected in the DISC (Fig 2A and B), showing that at least one
of its components is linearly ubiquitinated.
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Since FADD is required for TRAIL-induced cell death (Walczak
et al, 1997) and for formation of the TRAIL DISC (Kischkel et al,
2000; Sprick et al, 2000), we next evaluated the requirement of
FADD for LUBAC recruitment. Strikingly, the TRAIL complex I in
FADD KO A549 cells was devoid of LUBAC and linear ubiquitina-
tion as well as of caspase-8, RIPK1 and A20 (Fig 2C).
A B C
D E F
Figure 1. HOIP limits TRAIL-induced apoptosis and necroptosis.
A WT and HOIP KO TNF KO MEFs were stimulated with iz-TRAIL at the indicated concentrations for 24 h (n = 5; mean  SEM).
B WT and HOIP KO TNF KO MEFs, pre-treated with zVAD and Nec-1s as indicated for 1 h, were stimulated with iz-TRAIL for 24 h (1 lg/ml) (n = 4; mean  SEM).
C WT and HOIP KO TNF KO MEFs were stimulated with iz-TRAIL (1 lg/ml) for the indicated times. Lysates were analysed by Western blot.
D Control (CTRL) and HOIP KO K562 cells were stimulated with iz-TRAIL at the indicated concentrations for 24 h (n = 4; mean  SEM).
E Control and HOIP KO K562 cells, pre-treated with zVAD as indicated for 1 h, were stimulated with iz-TRAIL (1 lg/ml) for 24 h (n = 4; mean  SEM).
F Control and HOIP-deficient K562 cells were stimulated with iz-TRAIL (100 ng/ml) for the indicated times. Lysates were analysed by Western blot. Black arrowhead
indicates the cleaved form of HOIP.
Data information: Cell death was determined after 24 h of stimulation by flow cytometry after propidium iodide (PI) labelling. *P < 0.05, **P < 0.01, ***P < 0.001;
statistics were performed using t-test. See also Appendix Fig S1.
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Interestingly, a shorter form of HOIP whose appearance was
caspase-dependent was detected in various TRAIL-treated cell
lines (Figs 2A and B, and EV1C). Thus, LUBAC is recruited to the
TRAIL complex I in a FADD-dependent manner where it catalyses
linear ubiquitination and where HOIP also seems to be cleaved
by a caspase.
Caspase-8-dependent cleavage of HOIP at D348/D387/D390 does
not affect its apoptosis-preventing function
We next sought to elucidate the molecular basis of HOIP cleavage
upon TRAIL stimulation. We first evaluated whether active recombi-
nant caspases cleaved HOIP in vitro. Strikingly, treatment of cell
lysates or immuno-purified tap-tagged HOIP (HOIP-TAP) with
recombinant caspases 3, 6, 8 or 10a led to the cleavage of HOIP. By
contrast, the effector caspase-7, whilst being active against its
endogenous substrate PARP-1, was not able to cleave HOIP (Fig 3A
and Appendix Fig S2A). In MCF-7 cells, which do not express
caspase-3, knock-down (KD) of caspase-8 drastically reduced HOIP
cleavage induced by both, TRAIL and TNF. Conversely, KD of
caspase-6 in addition to caspase-8 did not further affect HOIP cleav-
age. Moreover, concomitant KD of caspases 6 and 10 did not
prevent HOIP cleavage (Fig 3B and Appendix Fig S2B). Therefore,
contrary to caspase-6 and caspase-10, caspase-8 cleaves HOIP upon
TRAIL stimulation in a cellular context.
We next determined whether caspase-3 also contributed to
HOIP cleavage. Whilst KD of caspase-8 substantially reduced
TRAIL- and TNF-induced HOIP cleavage, caspase-3 KD only
exerted a marginal effect (Fig 3C and Appendix Fig S2C). More-
over, by comparing HCT116 WT and BAX/BAK-DKO, we observed
that TRAIL-induced HOIP cleavage was similar at early time
points, whereas later it was slightly reduced in HCT116 BAX/BAK-
DKO in which caspase-3 was not fully activated (Fig 3D). In addi-
tion, whilst in both K562 (Fig 1F) and HT29 cells (Appendix Fig
S2D) caspase-8 activation and HOIP cleavage coincided, activation
of effector caspases occurred later. Interestingly, HOIP cleavage is
not limited to human cells since it also occurred in MEFs during
TNF-induced apoptosis (Appendix Fig S2E). Thus, caspase-8 is the
first and main caspase responsible for HOIP cleavage upon TRAIL
and TNF stimulation, whilst caspase-3 marginally contributes to it
at later time points.
We next sought to identify the caspase cleavage sites in HOIP to
investigate the effect of HOIP cleavage on its apoptosis-preventing
function. According to the apparent molecular weight of the cleav-
age fragment(s) observed, we narrowed down the cleavage sites
within a region spanning approximately amino acids 325–400
(Fig 3A and C). Within this region, GrabCas (Backes et al, 2005)
predicted two potential caspase-8 cleavage sites, D348 and D387.
In K562 HOIP KO cells reconstituted with HOIP D348A, the higher
N-terminal fragment band was still detected whilst the lower band
was not. Conversely, the shorter N-terminal fragment was still
visible in cells mutated for D387A (Fig 3E). Another study recently
described that HOIP is cleaved at D390, in addition to D348 and
D387 upon TNF stimulation (Joo et al, 2016). In accordance,
HOIP D348A/D387A/D390A (HOIPAAA) is completely resistant to
TRAIL-induced cleavage (Fig 3E). However, reconstitution of HOIP
KO K562 cells with HOIP WT or HOIPAAA equally rescued them
from TRAIL-induced death (Fig 3F).
We therefore conclude that whilst caspase-8, and to a lesser
extent caspase-3, cleaves HOIP upon TRAIL and TNF stimulation,
the TRAIL-induced cleavage of HOIP at D348/D387/D390 neither
prevents nor enhances its apoptosis-preventing function.
HOIP limits the activity of TRAIL-induced apoptosis- and
necroptosis-mediating signalling complexes
Since HOIP restricts TRAIL-induced apoptosis and is recruited to
complex I, we hypothesised that it influences formation and/or the
death-promoting activity of this complex. Indeed, activation of
caspase-8 was increased in HOIP KO cells, both in complex I and in
total lysates (Fig 4A). Additionally, in HOIP-deficient cells, ubiquiti-
nation of RIPK1 was reduced and its cleavage increased in complex
◀ Figure 2. LUBAC is recruited to the TRAIL complex I in a FADD-dependent manner.A HeLa cells, pre-treated for 1 h with zVAD as indicated, were treated with FLAG-lz-TRAIL (500 ng/ml) for the indicated times.
B A549 cells, pre-treated for 1 h with zVAD as indicated, were treated with FLAG-lz-TRAIL (500 ng/ml) for the indicated times.
C Control (CTRL) and FADD KO A549 cells, pre-treated for 1 h with zVAD, were treated with FLAG-lz-TRAIL (500 ng/ml) for the indicated times.
Data information: In all panels, the TRAIL complex I was immunoprecipitated via anti-FLAG beads and analysed by Western blot. Black arrowheads indicate the cleaved
form of HOIP. * indicates an unspecific band. See also Fig EV1.
◀ Figure 3. Caspase-8-dependent cleavage of HOIP at D348/D387/D390 does not alter its apoptosis-preventing function.A K562 WT lysates were incubated with 3 U of the indicated recombinant active caspases for 2 h at 37°C. Samples were then analysed by Western blot with the
indicated antibodies. Black arrowheads indicate the cleaved forms of HOIP.
B MCF-7 WT cells were transfected with the indicated combinations of siRNA control, siRNA targeting caspase-8, caspase-6 or caspase-10. 72 h later, cells were treated
with iz-TRAIL (1 lg/ml) for the indicated times. Lysates were analysed by Western blot. The black arrowhead indicates the cleaved form of HOIP.
C HeLa WT cells were transfected with the indicated combinations of siRNA control, siRNA targeting caspase-8 or caspase-3. 72 h later, cells were treated with iz-TRAIL
(1 lg/ml) for the indicated times. Lysates were analysed by Western blot. Black arrowheads indicate the cleaved forms of HOIP.
D WT and BAX/BAK-DKO HCT116 cells were treated with iz-TRAIL (1 lg/ml) for the indicated times and lysates were analysed by Western blot. Black arrowhead
indicates the cleaved form of HOIP.
E K562 HOIP KO reconstituted with HOIP WT, HOIP D348A, HOIP D387A or HOIP D348A/D387A/D390A (HOIPAAA) was incubated with iz-TRAIL (1 lg/ml) for the indicated
times and lysates were analysed by Western blot. Black arrowheads indicate the cleaved forms of HOIP.
F K562 HOIP KO reconstituted with empty vector, HOIP WT or HOIPAAA was incubated with the indicated concentrations of iz-TRAIL for 24 h before viability was
evaluated (n = 3; mean  SEM). *P < 0.05, **P < 0.01, ***P < 0.001, n.s, not significant; statistics were performed using ANOVA.
Data information: See also Appendix Fig S2.
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I as well as in a secondary TRAIL-induced cytoplasmic signalling
complex II, reflective of increased caspase-8 activity in both
complexes (Fig 4A). Notably, RIPK1 and TRAF2 are not only
components of TRAIL complex I but also of complex II (Figs 4A and
EV2A).
As HOIP deficiency can also sensitise cells to necroptosis when
RIPK3 and MLKL are expressed, we next studied how HOIP absence
affects the necroptotic machinery. Strikingly, HOIP deficiency
substantially increased formation of a FADD/RIPK1/RIPK3/MLKL-
containing complex upon TRAIL/zVAD stimulation (Fig 4B). Both
RIPK1 and RIPK3 were ubiquitinated in HOIP KO cells in this
complex. Moreover, MLKL phosphorylation, a modification required
for its pro-necroptotic activity (Sun et al, 2012), was increased in
HOIP KO cells (Fig 4B).
A20 is a deubiquitinase (DUB) which inhibits apoptosis (Jin et al,
2009; Bellail et al, 2012). As we and others recently found that A20
recruitment to the TNFR1-SC depends on linear ubiquitin (Tokunaga
et al, 2012; Verhelst et al, 2012; Draber et al, 2015), we next
assessed the role of HOIP in A20 recruitment to TRAIL-induced
signalling complexes. Notably, association of A20 with both, TRAIL
A B
Figure 4. HOIP limits the activity of TRAIL-induced apoptosis- and necroptosis-mediating signalling complexes.
A Control and HOIP KO HeLa cells were treated with FLAG-lz-TRAIL (500 ng/ml) for the indicated times. The TRAIL complex I was immunoprecipitated via anti-FLAG
beads. Complex II was isolated by immunoprecipitating caspase-8 from complex I-depleted lysates. Western blot was performed using the indicated antibodies.
* indicates unspecific bands.
B WT and HOIP-deficient TNF KO MEFs, pre-treated for 1 h with zVAD, were stimulated with iz-TRAIL (1 lg/ml) for the indicated times. FADD-containing complexes
were immunoprecipitated and analysed by Western blot.
Data information: See also Fig EV2.
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complex I and II, was completely HOIP-dependent (Figs 4A and B,
and EV2B and C). LUBAC is constitutively associated with two
DUBs, namely OTULIN and CYLD (Fiil et al, 2013; Elliott et al,
2014; Schaeffer et al, 2014; Takiuchi et al, 2014; Draber et al,
2015), both of which are important regulators of immune receptors
signalling (Shimizu et al, 2015; Damgaard et al, 2016; Elliott &
Komander, 2016). In TNF signalling, CYLD is recruited to the
TNFR1-SC via SPATA2 and LUBAC, whereas the linear ubiquitin-
specific DUB OTULIN is not, although the latter finding has been
controversial (Schaeffer et al, 2014; Draber et al, 2015; Elliott et al,
2016; Kupka et al, 2016; Schlicher et al, 2016; Wagner et al, 2016).
We therefore determined whether these DUBs form part of the
TRAIL signalling complexes. Whilst CYLD was recruited to TRAIL
complex I and to the TRAIL-induced necroptosis-mediating complex
in a HOIP-dependent manner, OTULIN did not form part of these
complexes (Fig EV2B and C). Interestingly, A20 recruitment to
TRAIL complex I was equally restored in A549 HOIP KO by re-
expression of HOIP WT or HOIPAAA, correlating with the accumula-
tion of linear linkages therein, whilst CYLD was not detectable in
these conditions probably due to its drastic caspase-dependent
cleavage (Fig EV2D).
Thus, HOIP is required for the recruitment of CYLD and A20 to
the TRAIL signalling complexes I and II and limits TRAIL-induced
apoptosis and necroptosis by modulating the formation and activity
of apoptosis- and necroptosis-mediating signalling complexes.
RIPK1 and caspase-8 are linearly ubiquitinated upon
TRAIL stimulation
As LUBAC and linear ubiquitin are detected in the TRAIL complexes
I and II, we next aimed to identify LUBAC target(s) in these
complexes. To do so, we first used M1-affinity purification (M1-AP)
to enrich for M1-ubiquitinated proteins (Draber et al, 2015). Inter-
estingly, both modified RIPK1 and caspase-8 were enriched by
M1-AP upon TRAIL stimulation in A549 cells (Fig 5A). To directly
assess the presence of M1 chains on RIPK1 and caspase-8, M1-AP
samples were treated with viral OTU (vOTU), with or without
concomitant OTULIN treatment. Whilst vOTU is a DUB able to
cleave all di-ubiquitin linkages except the M1-linkage, OTULIN
exclusively hydrolyses the latter (Keusekotten et al, 2013). OTULIN
reduced ubiquitination of both, caspase-8 and RIPK1, identifying
RIPK1 and caspase-8 as linearly ubiquitinated proteins (Fig 5A).
vOTU removed the majority of ubiquitin from RIPK1 and caspase-8
and resulted in the release of free linear ubiquitin chains, as demon-
strated by their cleavage in vOTU/OTULIN-cotreated samples
(Fig 5A). Thus, the M1 chains on RIPK1 and caspase-8 likely extend
from proximal ubiquitin chains of other linkage types, as previously
observed for other targets in different signalling complexes
(Emmerich et al, 2013). M1-ubiquitin immunoprecipitation (M1-IP)
from HOIP-proficient versus HOIP-deficient cells confirmed RIPK1
and caspase-8 as linearly ubiquitinated proteins in response to
TRAIL (Fig 5B and C).
The catalytic activity of HOIP contributes to preventing TRAIL-
induced apoptosis but is dispensable for inhibiting necroptosis
To evaluate whether linear ubiquitination contributes to the death-
inhibiting function of HOIP, we used HOIP KO K562 cells
reconstituted with empty vector, HOIP WT or the catalytically inac-
tive HOIP C885S (Fig 6A). Contrary to HOIP WT, HOIP C885S failed
to prevent TRAIL-induced RIPK1-kinase activity-independent apop-
tosis (Fig 6B). In line with this, HOIP WT, but not its catalytically
inactive version, limited TRAIL-induced cleavage of caspase-8,
caspase-3 and PARP-1 (Fig 6C). We next tested whether linear ubiq-
uitination also restricts TRAIL-induced necroptosis by reconstituting
HOIP KO MEFs with HOIP WT or C885S (Fig 6D). Interestingly,
both limited TRAIL/zVAD-induced cell death to a similar extent
(Fig 6E), thereby demonstrating that the activity of HOIP is dispens-
able for its necroptosis-preventing function. In HOIP-deficient MEFs,
TRAIL-induced cell death was completely abrogated by Nec-1s,
revealing a RIPK1-kinase-dependent type of cell death. Moreover,
these cells did not undergo necroptosis in the absence of zVAD, as
evaluated with the RIPK3 inhibitor GSK’872 (Fig 6F). Therefore,
HOIP KO MEFs are sensitised to TRAIL-induced RIPK1-kinase-
dependent apoptosis. Interestingly, the ubiquitin-ligase activity of
HOIP is partially required for protection against this type of cell
death (Fig 6E). Thus, HOIP’s catalytic activity is dispensable for
necroptosis protection whereas it is partially required for preventing
TRAIL-induced RIPK1-dependent apoptosis. In addition, linear ubiq-
uitination is essential for preventing RIPK1-independent apoptosis
upon TRAIL stimulation.
To understand the molecular mechanism underlying the role of
HOIP as a scaffold in the regulation of TRAIL-induced necroptosis,
we evaluated the formation of the necroptosis-inducing complex.
Expression of HOIP WT, but not HOIP C885S, limited the recruit-
ment of RIPK1 to FADD upon TRAIL/zVAD stimulation. Interest-
ingly, however, the accumulation of RIPK3, which was heavily
ubiquitinated in this complex, was limited by both HOIP WT and
HOIP C885S, correlating with their ability to prevent TRAIL-induced
necroptosis (Fig 6G). Hence, HOIP acts as a scaffold to prevent
TRAIL-induced necroptosis.
HOIP promotes TRAIL-induced gene-activatory signalling and the
ensuing cytokine production
Besides triggering cell death, TRAIL can also induce cytokine
production via DD-dependent activation of NF-jB and MAPK path-
ways (Wajant et al, 2000; Harper et al, 2001; Leverkus et al, 2003;
Varfolomeev et al, 2005; Trauzold et al, 2006; Tang et al, 2009;
Azijli et al, 2013). We therefore investigated whether LUBAC influ-
ences TRAIL-induced gene-activatory signalling. Remarkably,
TRAIL-induced NF-jB activation was consistently impaired in
absence of HOIP in K562, HeLa, HT29 and A549 cells as well as in
inducible HOIP KO primary bone marrow-derived macrophages
(BMDMs) (Figs 7A and B, and EV3A and B, and EV4B). Moreover,
re-expression of HOIP WT in HOIP KO A549, K562 and HT29 cells
restored TRAIL-induced NF-jB activation (Figs 7B and C and
EV4B). Similar results were observed upon TNF stimulation in HeLa
as well as BMDMs (Fig EV3C and D).
In addition to NF-jB, activation of p38, JNK and ERK was consis-
tently impaired in both HOIP KO HeLa and BMDMs in response to
TNF (Fig EV3C and D). By contrast, among the cell types tested,
absence of HOIP impaired TRAIL-induced p38 and JNK phosphory-
lation only in HT29 cells (Fig EV4B). Interestingly, HOIP-deficient
K562, HeLa and HT29 cells showed an impairment of TRAIL-
induced ERK activation (Figs 7A and C, and EV4B), which we
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Figure 5. RIPK1 and caspase-8 are linearly ubiquitinated upon TRAIL stimulation.
A A549 WT cells, pre-treated for 1 h with zVAD, were treated with iz-TRAIL (500 ng/ml) for 1 h and lysed in denaturing conditions. Linear ubiquitin affinity purification
(M1-AP) was performed, with subsequent treatment with the indicated DUBs (1 lM), and samples were analysed by Western blot.
B Control and HOIP KO A549 cells, pre-treated with zVAD for 1 h, were treated with iz-TRAIL (500 ng/ml) for 1 h and lysed in denaturing conditions. Linear ubiquitin
immunoprecipitation (M1-IP) was performed, and samples were analysed by Western blot.
C Control and HOIP KO HeLa cells, pre-treated with zVAD for 1 h, were treated with iz-TRAIL (500 ng/ml) for 1 h and lysed in denaturing conditions. Linear ubiquitin
immunoprecipitation (M1-IP) was performed, with subsequent treatment with vOTU (1 lM), and samples were analysed by Western blot.
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further investigated. Since IKK can trigger activation of MEK1/2
(Gantke et al, 2011; Sasaki et al, 2013), we hypothesised that
TRAIL-induced activation of ERK could be IKK-dependent. Indeed,
inhibition of IKK limited TRAIL-induced phosphorylation of IjBa
and ERK in K562 cells (Fig EV3E). Moreover, whilst gene activation
can suppress TRAIL-induced cell death (Ehrhardt et al, 2003; Luo
et al, 2004; Roue´ et al, 2007; Jennewein et al, 2012; Geismann et al,
2014; Jeon et al, 2015), HOIP KO cells were still sensitised to
TRAIL-induced apoptosis in the presence of cycloheximide
(Fig EV3F). Our earlier data suggested that TRAIL-induced HOIP
cleavage removes its PUB, ZF and NZF1 domains. Since the PUB
domain mediates the interaction with CYLD and OTULIN (Schaeffer
et al, 2014; Takiuchi et al, 2014; Draber et al, 2015) and the ZF and
NZF1 are required for HOIP binding to ubiquitin and NEMO (Haas
et al, 2009; Ikeda et al, 2011; Fujita et al, 2014), we hypothesised
that cleavage of HOIP may modulate TRAIL-induced gene activa-
tion. However, re-expression of HOIP WT or HOIPAAA equally
restored TRAIL-induced activation of NF-jB and MAPKs in HOIP KO
cells (Fig EV4A–D). Thus, HOIP consistently promotes activation of
NF-jB and, in certain cell types, participates in MAPK activation.
However, like the cell-death-limiting function, also the gene-
activatory capacity of HOIP is not affected by its caspase-dependent
cleavage.
As a functional consequence of impaired gene-activatory signal-
ling, TRAIL-induced production of IL-8 and CCL-2 was largely
reduced in both HOIP KO A549 and HeLa cells (Fig 7D and E).
Interestingly, whilst inhibition of IKKa/b, MEK1/2, JNK1/2 and
p38a/b all diminished TRAIL- and TNF-induced cytokine produc-
tion, that of IKKa/b/IjBa/NF-jB was most potent in doing so
(Appendix Fig S3A–C). In accordance, KD of p65 consistently
reduced IL-8 and CCL-2 production upon both TRAIL and TNF
stimulation (Fig 7F and G). Therefore, NF-jB signalling, which is
consistently affected by absence of HOIP, is crucial for TRAIL- and
TNF-induced pro-inflammatory cytokine production.
HOIP acts downstream of FADD, caspase-8 and cIAP1/2 to recruit
the IKK complex to the TRAIL complex I
We next aimed to understand how HOIP promotes TRAIL-induced
NF-jB activation. Surprisingly, the IKK complex was recruited to
the TRAIL-R-associated complex I (Fig 8A), which was so far
thought to exclusively act as a DISC. Recruitment of the IKK
complex and HOIP to complex I occurred concomitantly and was
precisely reflected in the kinetics of degradation of IjBa, a func-
tional consequence of IKK activation. Strikingly, in HOIP KO cells
TRAIL-induced recruitment and activation of the IKK complex was
not detectable in complex I (Figs 8A and EV5A). In addition, activa-
tion of the IKK complex in complex II was also HOIP-dependent
(Fig EV5A).
We next wanted to define the sequence of events leading to
complex I assembly. Since FADD, caspase-8, RIPK1 and cFLIPL/S
regulate TRAIL-induced NF-jB activation (Lin et al, 2000;
◀ Figure 6. The catalytic activity of HOIP contributes to preventing TRAIL-induced apoptosis but is dispensable for preventing necroptosis.A Lysates from control or HOIP KO K562 cells reconstituted with empty vector, HOIP WT or HOIP C885S were analysed by Western blot.
B HOIP KO K562 cells reconstituted with empty vector, HOIP WT or HOIP C885S, pre-treated with zVAD and/or Nec-1s for 1 h as indicated, were treated with iz-TRAIL
(1 lg/ml) for 24 h. Percentage of cell death was determined by flow cytometry after PI labelling (n = 5; mean  SEM). *P < 0.05, **P < 0.01; statistics were
performed using ANOVA.
C Control and HOIP KO K562 cells reconstituted with empty vector, HOIP WT or HOIP C885S were treated with iz-TRAIL (100 ng/ml) for the indicated times. Lysates
were analysed with the indicated antibodies.
D Lysates from TNF KO HOIP KO MEFs reconstituted with empty vector, HOIP WT or HOIP C885S were analysed by Western blot.
E TNF KO HOIP KO MEFs reconstituted with empty vector, HOIP WT or HOIP C885S, pre-treated with zVAD and Nec-1s for 1 h as indicated, were treated with iz-TRAIL
(1 lg/ml) for 24 h. Percentage of cell death was determined by flow cytometry after PI labelling (n = 4; mean  SEM). *P < 0.05, ***P < 0.001; statistics were
performed using ANOVA.
F TNF KO HOIP KO MEFs reconstituted with empty vector, pre-treated with zVAD and/or the RIPK3 inhibitor GSK’872 for 1 h as indicated, were treated with iz-TRAIL
(1 lg/ml) for 24 h. Percentage of cell death was determined by flow cytometry after PI labelling (n = 3; mean  SEM). *P < 0.05; statistics were performed using
t-test.
G TNF KO HOIP KO MEFs reconstituted with empty vector, HOIP WT or HOIP C885S, pre-treated with zVAD for 1 h, were treated with iz-TRAIL (1 lg/ml) for the
indicated times. FADD-containing complexes were immunoprecipitated and analysed by Western blot.
◀ Figure 7. HOIP promotes TNF- and TRAIL-induced gene-activatory signalling and ensuing cytokine production.A Control and HOIP KO HeLa cells were stimulated for the indicated times with iz-TRAIL (100 ng/ml), and lysates were analysed by Western blot.
B HOIP KO A549 cells reconstituted with empty vector or HOIP WT were treated with iz-TRAIL (200 ng/ml) for the indicated times, and lysates were analysed by
Western blot.
C HOIP-deficient K562 cells reconstituted with empty vector or HOIP WT were stimulated for the indicated times with iz-TRAIL (1 lg/ml). Lysates were analysed by
Western blot.
D WT and HOIP KO A549 cells reconstituted with empty vector or with HOIP WT were pre-treated with QVD (10 lM) for 1 h and further treated with iz-TRAIL (100 ng/
ml) for 24 h as indicated. IL-8 and CCL-2 concentrations in culture supernatants were measured via ELISA (n = 3; mean  SEM).
E Control and HOIP KO HeLa cells were pre-treated with QVD (10 lM) for 1 h and further treated with iz-TRAIL (100 ng/ml) or His-TNF (50 ng/ml) for 24 h as
indicated. IL-8 and CCL-2 concentrations in culture supernatants were measured via ELISA (n = 3; mean  SEM).
F WT A549 cells were transfected with siRNA control or targeting p65. 72 h later, cells were pre-treated with QVD (10 lM) for 1 h and further treated with iz-TRAIL
(100 ng/ml) or His-TNF (50 ng/ml) for 24 h as indicated. IL-8 and CCL-2 concentrations in culture supernatants were measured via ELISA (n = 4; mean  SEM).
Lysates were analysed by Western blot.
G WT HeLa cells were transfected with siRNA control or targeting p65. 72 h later, cells were pre-treated with QVD (10 lM) for 1 h and further treated with iz-TRAIL
(100 ng/ml) or His-TNF (50 ng/ml) for 24 h as indicated. IL-8 and CCL-2 concentrations in culture supernatants were measured via ELISA (n = 4; mean  SEM).
Lysates were analysed by Western blot.
Data information: See also Figs EV3 and EV4, and Appendix Fig S3.
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Varfolomeev et al, 2005; Siegmund et al, 2007; Kavuri et al, 2011;
Grunert et al, 2012) and cIAP1/2 recruit LUBAC to various signal-
ling complexes (Haas et al, 2009; Varfolomeev et al, 2012), we
assessed the role of these factors in LUBAC recruitment and IKK
activation to complex I. We found that FADD was required for
recruitment of caspase-8, cFLIPL, RIPK1, cIAP1/2 and LUBAC to
complex I (Figs 2C and EV5B). Furthermore, KD of caspase-8
substantially reduced recruitment of cFLIPL/S, RIPK1, cIAP1/2 and
HOIP to, as well as activation of IKKa/b in, this complex (Fig 8B).
By contrast, silencing of RIPK1 did not affect recruitment of the
other complex I components (Fig 8B). Strikingly, depletion of
cFLIPL/S resulted in enhanced recruitment of caspase-8, RIPK1, A20
and HOIP to complex I and, accordingly, to increased linear ubiqui-
tination and enhanced phosphorylation of IKKa/b. Notably, A20, a
known NF-jB target gene, was strongly induced upon TRAIL stimu-
lation in cFLIPL/S KD cells (Fig 8C). Lastly, depletion of cIAP1/2 by
treatment with SMAC mimetics reduced the recruitment of LUBAC
and A20 and the accumulation of linear ubiquitin as well as phos-
phorylation of IKKa/b in complex I whilst recruitment of FADD,
caspase-8 and TRAF2 was unaffected (Fig 8D). In summary, LUBAC
promotes recruitment of the IKK complex to the TRAIL-R-associated
complex I, downstream of FADD, caspase-8 and cIAP1/2, yet inde-
pendently of RIPK1 (Fig EV5C).
Discussion
Posttranslational modifications, including phosphorylation and
ubiquitination, are major modulators of immune signalling. Here,
we provide evidence for LUBAC as a previously unrecognised regu-
lator of TRAIL-induced NF-jB activation, apoptosis and necroptosis
by acting in both, complex I and complex II of TRAIL signalling.
Importantly, we establish that TRAIL complex I not only recruits
death-mediating factors but also gene-activatory factors, thereby
initiating the molecular events leading to gene activation. We iden-
tify FADD as essential for recruitment of all complex I components
studied. Hence, FADD, which acts as the first interactor with TRAIL-
Rs (Kischkel et al, 2000; Sprick et al, 2000) and is required for
TRAIL-induced apoptosis (Walczak et al, 1997), serves as the apical
factor for all DD-dependent TRAIL signalling outputs. Although
cFLIPL/S can interact directly with FADD, caspase-8 depletion
decreases its recruitment to complex I, consistent with a previous
report showing that its recruitment to complex I is mainly mediated
by direct interaction with caspase-8 (Hughes et al, 2016). Intrigu-
ingly, both FADD and caspase-8 are required for recruitment of
RIPK1 to the TRAIL complex I, implying that caspase-8 might stabi-
lise a DD-mediated FADD-RIPK1 interaction. Downstream of
caspase-8, TRAF2 recruits cIAP1/2, promoting recruitment of
LUBAC and ubiquitination of RIPK1 and caspase-8. LUBAC ulti-
mately limits caspase-8 activation and recruits the IKK complex,
likely due to the ability of NEMO to bind linear chains (Rahighi
et al, 2009).
In addition to recruiting IKK to complex I and limiting caspase-8
activation, HOIP also mediates recruitment of A20 and CYLD, which
might in turn restrict IKK activation, as suggested for TNF signalling
(Tokunaga et al, 2012; Verhelst et al, 2012; Draber et al, 2015). In
addition, cFLIPL/S acts as a negative regulator of RIPK1, caspase-8
and HOIP recruitment, thereby restricting accumulation of linear
ubiquitination and IKK activation in complex I. Importantly, by
showing that HOIP mediates recruitment of the IKK complex to
complex I of TRAIL signalling, our study extends the current model
of TRAIL-induced gene-activatory signalling according to which this
type of signalling outcome emanates from complex II (Varfolomeev
et al, 2005) whilst complex I would be responsible for induction of
cell death. According to the revised model for TRAIL signalling
(Fig EV5C) and, interestingly, in contrast to TNF signalling, both
TRAIL-induced complexes I and II can initiate gene activation as
well as cell death with LUBAC playing a crucial role in determining
which signalling outcomes emanate from these complexes.
As observed also upon TNF stimulation, absence of HOIP never
fully abrogated but rather attenuated and delayed phosphorylation
of IjBa. Interestingly, Zhang and colleagues suggested that whilst
HOIP might contribute to the early activation of NF-jB, a delayed
LUBAC-independent NF-jB activation pathway, which would
involve caspase-3 activation and the protein MEKK1, is also induced
by TRAIL (Zhang et al, 2015). In addition, whilst NEMO preferen-
tially binds to linear ubiquitin chains, it is able to bind K63 chains,
albeit with less affinity (Rahighi et al, 2009). Therefore, and despite
the fact that we did not detect IKK in complex I and II in the absence
of HOIP, one could speculate that the presence of K63 chains in
these complexes could allow for suboptimal recruitment and activa-
tion of IKK, explaining the observed residual IjBa activation.
Further work will be needed to precisely define these LUBAC-
independent alternative pathways leading to NF-jB activation as
well as the molecular mechanisms of their initiation from complex I,
II or perhaps additional, yet-to-be-defined TRAIL-induced signalling
complexes.
We show that LUBAC is present in the TRAIL-R-associated
complex I and the secondary complex II upon TRAIL stimulation
and that it forms linear ubiquitin chains in both complexes. We
specifically identify RIPK1 and caspase-8 as M1-ubiquitinated
proteins following TRAIL stimulation and HOIP’s catalytic activity
as required for preventing RIPK1-kinase-independent apoptosis.
Upon TNF stimulation, linear ubiquitination of RIPK1, but also
▸Figure 8. HOIP-mediated recruitment of the IKK complex to TRAIL complex I is caspase-8- and cIAP1/2-dependent, RIPK1-independent and negativelyregulated by cFLIPL/S.
A Control and HOIP KO A549 cells, pre-treated for 1 h with zVAD, were treated with FLAG-lz-TRAIL (500 ng/ml) for the indicated times.
B A549 WT cells were transfected with siRNA control, siRNA targeting caspase-8 or targeting RIPK1. 72 h later, cells were pre-treated with zVAD for 1 h and treated
with FLAG-lz-TRAIL (500 ng/ml) for 1 h.
C A549 WT cells were transfected with siRNA control or targeting cFLIPL/S. 72 h later, cells were pre-treated with zVAD for 1 h and treated with FLAG-lz-TRAIL (500 ng/
ml) for 1 h.
D A549 WT cells, pre-treated with zVAD and SM for 1 h as indicated, were treated with FLAG-lz-TRAIL (500 ng/ml) for the indicated times.
Data information: In all panels, TRAIL complex I was immunoprecipitated via anti-FLAG beads and samples were analysed by Western blot. See also Fig EV5.
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TRADD, NEMO and TNFR1, occurs at the TNFR1-SC (Haas et al,
2009; Gerlach et al, 2011; Draber et al, 2015), stabilising this gene-
activatory complex and limiting the formation of the death-inducing
complex II. Similarly, in TRAIL signalling, RIPK1 association with
complex I is reduced and it accumulates in complex II in absence of
HOIP. Furthermore, we identify a novel role played by linear ubiqui-
tination in preventing TRAIL-induced apoptosis by discovering that
HOIP limits caspase-8 activity in both, complex I and II. It will be
interesting to determine whether this function is a direct conse-
quence of linear ubiquitination of caspase-8 or results from an indi-
rect mechanism. Within complex I and II, we found that caspase-8
itself cleaves HOIP. However, this neither abrogated HOIP’s cell-
death-limiting function nor its ability to enhance gene activation.
This could be explained by a sufficient amount of linear ubiquitina-
tion already accumulating on components of complex I and II which
could promote IKK recruitment and restrict caspase-8 activity before
a substantial amount of HOIP would be processed.
Presence but not activity of HOIP is required for prevention of
TRAIL-induced necroptosis. The same applies to the association of
RIPK3 with RIPK1 and ubiquitination of RIPK3. RIPK3 is also ubiq-
uitinated during TNF-induced necroptosis, which was suggested to
support the association of RIPK3 with RIPK1 (Onizawa et al, 2015).
It remains to be determined whether TRAIL-induced RIPK3 ubiquiti-
nation also promotes necroptosis. Yet, according to our results, the
E3-ligase(s) and/or DUB(s) responsible for its accumulation are
likely to be regulated by HOIP independently of its activity. Given
the demonstrated function of CYLD in necroptosis (Hitomi et al,
2008; O’Donnell et al, 2011), it is unlikely to account for HOIP’s
protective role in necroptosis despite being recruited to complex I
and II together with LUBAC.
In conclusion, LUBAC and M1-ubiquitin chains are previously
unrecognised components of complex I and II of TRAIL signalling.
Within both complexes, LUBAC limits activation of caspase-8 and
promotes IKK complex recruitment, thereby restricting apoptosis
and driving pro-inflammatory cytokine production. In addition,
LUBAC restricts TRAIL-induced necroptosis by limiting the forma-
tion of the necroptosis-mediating complex. It will be interesting to
define how particular deubiquitination events in turn modulate
TRAIL-induced signalling. In the light of our findings, the addition
of SMAC mimetics, which we found limit LUBAC recruitment to
complex I, or LUBAC inhibitors, may improve anti-cancer therapeu-
tic effects of TRAIL-R agonists through distinct mechanisms, that is
not only by increasing the cancer cell-killing efficiency (Geserick
et al, 2009; Basit et al, 2012; Abhari et al, 2013; Fulda, 2014) but
also by interfering with the creation of a pro-tumorigenic microenvi-
ronment by preventing surviving cancer cells from producing
tumour-promoting cytokines.
Materials and Methods
Viability and cell-death assays
Cells, pre-treated with zVAD-fmk (20 lM, Abcam), Nec-1s (10 lM,
Biovision), cycloheximide (0.5 lg/ml, Sigma), GSK’872 (1 lM,
Biovision) for 1 h as indicated, were treated for 24 h with the indi-
cated concentrations of iz-human TRAIL (for HeLa and K562 cells)
or iz-murine TRAIL (for MEFs). For cell-death assays, the
supernatant was then collected, remaining attached cells were
trypsinised, and both were combined and centrifuged at 806 g for
5 min. The pellet was resuspended with PBS containing 5 lg/ml
propidium iodide (PI) (Sigma). Data were acquired on BD Accuri C6
or alternatively BD LSR Fortessa X20, and the percentage of
PI-positive cells was determined by data analysis using FlowJo
7.6.5. For cell viability, Cell Titer Glo (Promega) was used,
according to the manufacturer’s protocol.
Cell stimulation, TRAIL complex I, complex II, FADD and HOIP
immunoprecipitations
For gene-activatory signalling kinetics, cells seeded in 6-well plates
were incubated overnight and stimulated in serum-free medium. For
immunoprecipitations, cells were washed with PBS twice and stimu-
lated in serum-free medium. Whenever stated, cells were pre-treated
with SM-083 (100 nM) with or without zVAD (20 lM) or TPCA-1
(5 lM, Tocris) for 1 h. For TRAIL complex I IP, cells were stimu-
lated with FLAG-lz-TRAIL as indicated. Cells were lysed in IP-lysis
buffer (30 mM Tris–HCl, pH 7.4, 120 mM NaCl, 2 mM EDTA, 2 mM
KCl, 10% glycerol, 1% Triton X-100, 1× COMPLETE protease-inhi-
bitor cocktail and 1× PhosSTOP (Roche)) at 4°C for 30 min. Lysates
were cleared by centrifugation at 17,000 g for 30 min. FLAG-lz-
TRAIL (200 ng) was added to the non-stimulated samples before all
samples were pre-cleared using Sepharose beads (Sigma) for 1 h at
4°C. 15 ll of M2 beads (Sigma) were then added to the samples and
incubated overnight at 4°C. To analyse the complex II, the complex
I-depleted lysates were collected and incubated overnight at 4°C
with 15 ll protein G beads pre-blocked with 1% BSA and coupled
with 3 lg anti-caspase-8 antibody (Santa Cruz Biotechnology, clone
C20). For FADD IP, cells were stimulated with iz-murine TRAIL and
zVAD as indicated and lysates were prepared as described for the
TRAIL complex I IP. 15 ll of protein G beads pre-blocked in 1%
BSA and coupled with 3 lg anti-murine FADD antibody (Santa Cruz
Biotechnology, clone M19) were added to the supernatants and
incubated overnight at 4°C. For HOIP IP, cells expressing HOIP-TAP
or empty vector were stimulated with iz-human TRAIL and zVAD as
indicated and samples were processed as indicated for TRAIL
complex I IP. After all IPs, beads were washed 4 times with IP-lysis
buffer and incubated with LDS containing 5 mM DTT at 95°C for
5 min before Western blot analysis.
Isolation of linearly ubiquitinated proteins by
immunoprecipitation (M1-IP) and affinity purification (M1-AP)
For M1-IP, cells were lysed in M1-IP lysis buffer (5 M urea, 135 mM
NaCl, 1% Triton X-100, 1.5 mM MgCl2, 2 mM N-ethylmaleimide,
1% SDS, 1× COMPLETE protease-inhibitor and 1× PhosSTOP
(Roche)). Lysates were incubated 20 min on ice, sonicated and
cleared by centrifugation at 17,000 g for 30 min. Lysates were pre-
cleared with Sepharose beads (Sigma) and incubated with 0.25 lg
antibody per sample (linear ubiquitin antibody, clone 1E3, Milli-
pore) overnight at room temperature. Protein G beads (GE Health-
care) were added for 2 h, and beads were washed twice with M1-IP
lysis buffer and twice with PBS before performing DUB assay.
For M1-AP, cells were lysed in AP-lysis buffer (30 mM Tris–HCl,
pH 7.4, 120 mM NaCl, 2 mM EDTA, 2 mM KCl, 0.5% CHAPS, 1%
SDS, 1× COMPLETE protease-inhibitor and 1× PhosSTOP (Roche)).
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Lysates were incubated 10 min on ice, sonicated and cleared by
centrifugation at 17,000 g for 30 min. The M1-AP tool was produced
as described previously (Draber et al, 2015). Samples were diluted
to 0.1% SDS before M1-ubiquitin-specific recombinant affinity
protein freshly pre-coupled to HALO beads (Promega) was added
for overnight incubation at 4°C. Beads were washed three times
using AP-lysis buffer deprived of SDS, proteases and phosphatases
inhibitors before undergoing DUB assay.
Deubiquitination assay
Recombinant viral OTU and OTULIN were produced as described
previously (Draber et al, 2015). After the washes, beads were
resuspended in DUB reaction buffer (50 mM Tris (pH 7.5), 50 mM
NaCl and 5 mM DTT) with or without 1 lM recombinant deubiqui-
tinase and incubated for 1 h at 37°C. Reaction was stopped by
adding LDS (Invitrogen) with 5 mM DTT, and samples were
reduced and denatured by incubation for 10 min at 70°C before
Western blot analysis.
Caspase assay
K562 cells were lysed in caspase assay lysis buffer [30 mM Tris–
HCl, pH 7.4, 120 mM NaCl, 2 mM EDTA, 2 mM KCl, 10% glycerol,
1% Triton X-100, 1× PhosSTOP (Roche), 5 mM DTT, AEBSF 70 lM
and pepstatin A (1 lM)], at 4°C for 30 min. Lysates were cleared by
centrifugation at 17,000 g for 30 min. 3 U of active caspases 7, 6
(Enzo Life Sciences), 3, 8 or 10a (produced by Martin Sprick) was
added to the cleared lysates and incubated for 2 h at 37°C. The reac-
tion was stopped by adding LDS (Invitrogen) with 5 mM DTT, and
samples were reduced and denatured by incubation for 10 min at
70°C before Western blot analysis.
TAP-HOIP was immunoprecipitated from K562-HOIP-TAP
expressing cells as described earlier. After 4 washes in IP-lysis
buffer, the beads were resuspended with caspase assay buffer
(20 mM HEPES, pH 7.4, 0.1% CHAPS, 5 mM DTT, 2 mM EDTA,
5% sucrose) containing 3 U of recombinant caspases 7, 6, 3, 8 or
10a and incubated for 2 h at 37°C. The reaction was stopped by
adding LDS (Invitrogen) with 5 mM DTT, and samples were
reduced and denatured by incubation for 10 min at 70°C before
Western blot analysis.
Electrophoresis and Western blot
Proteins were separated using 4–12% Bis–Tris–NuPAGE gels (Invit-
rogen) with NuPAGE MOPS running buffer. Alternatively, 4–15%
Mini-PROTEAN TGXTM Precast Protein Gels and TGX buffer (Bio-
Rad) were used. Proteins were transferred from gels onto ECL-
Membrane Hybond 0.45-lm nitrocellulose membrane (GE Health-
care). Alternatively, the Trans Blot TurboTM System (Bio-Rad) was
used. Whenever necessary, 50 mM glycine, pH 2.3 was used as
stripping buffer in between antibody incubations.
ELISA
A549 and HeLa cells were pre-treated with QVD-OPh (10 lM,
Abcam) for 1 h, with or without TPCA-1 (10 lM), SP600125
(15 lM), losmapimod (5 lM) or PD184352 (1 lM), and further
stimulated with iz-human TRAIL (100 ng/ml) for 24 h as indicated.
Medium was collected and centrifuged at 405 g for 3 min. IL-8 and
CCL2 concentrations were determined in the resulting supernatants
via ELISA obtained from R&D, according to the manufacturer’s
instructions.
Production of recombinant TRAIL and TNF
Iz-human TRAIL and iz-murine TRAIL were produced and purified
as described previously (Ganten et al, 2006). The sequences coding
for FLAG-lz-TRAIL, consisting of a His-tag followed by 1xFLAG, a
PreScission cleavage site, 2xStrep-tag II, a leucine zipper motif and
part of the extracellular portion of human TRAIL (aa 120–281) were
inserted into the pQE30 vector. FLAG-lz-TRAIL was then produced
and purified as described previously for TAP-TNF (Draber et al,
2015). Iz-human TRAIL, iz-murine TRAIL and FLAG-lz-TRAIL were
tested as LPS-free using Pierce LAL Chromogenic Endotoxin Quanti-
tation Kit (Thermo Scientific). His-TNF was produced as described
previously (Draber et al, 2015).
siRNA-mediated knock-down
All siRNAs used were ON TARGET Plus SMART pool from Dharma-
con, non-targeting, targeting cFLIPL/S, caspase-8, RIPK1 or p65.
A549 WT cells were reverse-transfected in 10-cm dishes, using 14 ll
of Dharmafect I (GE Healthcare)/dish and 40 nM siRNA pools. Cells
were stimulated 72 h after transfection.
Cell lines and antibodies
WT cell lines were purchased from ATCC. HOIP-deficient HT29 cells
were generated by transfection with pSpCas9(BB)-2A-GFP (PX458,
Addgene plasmid #48138) (Ran et al, 2013) containing the following
gRNA-encoding sequence targeting exon 2 of RNF31: CACCGTTGA
CACCACGCCAGTACCG. GFP-positive cells were sorted into 96-
wells plates, and single-cell clones were analysed 4 weeks later by
Western blot to assess KO efficiency. All the other KO and reconsti-
tuted cell lines used were described previously (Peltzer et al, 2014;
Draber et al, 2015; von Karstedt et al, 2015). For reconstitution of
HOIP KO cells with HOIP WT and HOIPD348A, HOIPD387A and
HOIPD348A/D387A/D390A, the different versions of HOIP were
generated by site-directed mutagenesis and inserted into pBabe-puro
(Addgene) and Phoenix-Ampho cells were transfected. A549, HT29
and K562 HOIP KO cells were infected with the obtained viral super-
natants and then selected with puromycin for 4 weeks. All cell lines
were regularly tested for mycoplasma using MycoAlertTM Myco-
plasma Detection Kit (LONZA). For the isolation of BMDMs,
4-hydroxytamoxifen (4-OHT)-inducible CreERT2+ Hoipfl/fl mice
were sacrificed. After removal of the hindlimbs, muscle tissue was
carefully removed from femur and tibia. Both bones were cut on
their extremes, and the bone marrow content was flushed out with
PBS using a 25-G needle. The obtained cells were passed through a
cell strainer and washed with PBS. Erythrocytes were lysed by
resuspension in 2 ml of red blood cell lysis buffer (eBioscience) and
incubation for 1 min. Finally, cells were washed and resuspended in
conditioned medium (RPMI medium containing 20% foetal calf
serum (FCS), 1% penicillin/streptomycin (Invitrogen) and 20%
conditioned medium from L929 cells) and seeded in 6-well plate.
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The cells were incubated for 7 days before the experiment, replacing
the conditioned medium every 2 days. To induce deletion of the
HOIP gene, tamoxifen was added 3 days before the experiment to
half of the wells at a final concentration of 1 lM. In addition, Enbrel
(50 lg/ml, Amgen) was also added to all the wells to avoid auto-
crine stimulation by TNF. This medium was replaced daily until the
experiment was performed.
The following primary antibodies were used for Western blot:
cleaved murine caspase-8 (Cell Signaling, 9429), cleaved caspase-3
(Cell Signaling, 9664), caspase-3 (Cell Signaling, 9668), caspase-10
(MBL, M059-3), murine caspase-8 (Enzo Life Sciences, ALX-804-
447-C100), caspase-8 (Enzo Life Sciences, C15), cFLIPL/S (Enzo Life
Sciences, NF6), Bid (Cell Signaling, 2002), TRAF2 (Enzo Life
Sciences, ADI-AAP-422), FADD (Enzo Life Sciences, 1F7), TRAIL-R2
(Cell Signaling, 3696), TRAIL-R1 (ProSci, 1139), FADD (BD,
556402), RIPK1 (BD, 610459), cIAP1/2 (R&D, MAB3400) FADD
(Santa Cruz Biotech, sc-5559), PARP-1 (BD, 556362), HOIL-1 (Haas
et al, 2009), SHARPIN (Proteintech, 14626-1-AP), A20 (Santa Cruz
Biotech, sc-166692), HOIP (Aviva Systems Biology, ARP43-
241_P050), linear ubiquitin (Millipore, MABS199), p-MLKL (Abcam,
ab196436), RIPK3 (Novus, IMG-5846A), murine RIPK3 (Enzo Life
Sciences, ADI-905-242-100), NEMO (Santa Cruz Biotech, sc-8330),
p-IKK a/b (Cell Signaling, 2697), p-IjBa (Cell Signaling, 9246), IjBa
(Cell Signaling, 9242), p105 (Cell Signaling, 4717), p-p105 (Cell-
Signaling, 4806), p-MEK1/2 (Cell Signaling, 9154), p-ERK1/2
(Cell Signaling, 4370), ERK1/2 (Cell Signaling, 4695), p-JNK (Cell
Signaling, 4671), JNK (Cell Signaling, 9258) p-p38 (Cell Signaling,
9215), p38 (Santa Cruz Biotech, sc-728), Flag (Sigma, M2), actin
(Sigma, A1978), p-c-Jun (Cell Signaling, 9261), c-Jun (Cell
Signaling, 9165), p-CREB (Cell Signaling, 9198), CREB (Cell
Signaling, 9197), HOIP (R&D, AF8039), CYLD (Santa Cruz Biotech,
sc-74435), OTULIN (Abcam, ab151117).
Statistics
GraphPad Prism 6 (GraphPad software version 6.01) was used for
data analysis. Statistical significance between groups was evaluated
by two-sided unpaired t-test and a two-way ANOVA test whenever
performing multiple comparisons, as indicated. Alternatively,
and as indicated, a Mann–Whitney U-test was used. Whenever
relevant, the assumptions of normality and equality of variance were
verified using the Shapiro–Wilk test and the F-test, respectively.
P-values < 0.05 are indicated and considered as statistically
significant.
Expanded View for this article is available online.
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